This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.